Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 3/2018

Open Access 01-03-2018 | Review

World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat

Authors: Hidekazu Suzuki, Hideki Mori

Published in: Journal of Gastroenterology | Issue 3/2018

Login to get access

Abstract

Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.
Literature
1.
Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15(3):306–16 (Epub 2014/03/19).CrossRefPubMed
2.
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9 (Epub 2001/09/15).CrossRefPubMed
3.
4.
Suzuki H, Mori H. Helicobacter pylori: Helicobacter pylori gastritis-a novel distinct disease entity. Nat Rev Gastroenterol Hepatol. 2015;12(10):556–7 (Epub 2015/09/16).CrossRefPubMed
5.
Suzuki H, Mori H. Different pathophysiology of gastritis between East and West? An Asian perspective. Inflamm Intest Dis. 2016;1(3):123–8.CrossRef
6.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86 (Epub 2014/09/16).CrossRefPubMed
7.
Adamu MA, Weck MN, Gao L, et al. Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. Eur J Epidemiol. 2010;25(7):439–48 (Epub 2010/06/30).CrossRefPubMed
8.
Jaskiewicz K, Louwrens HD. Chronic atrophic gastritis in a population at risk for gastric carcinoma. Anticancer Res. 1991;11(2):835–9 (Epub 1991/03/01).PubMed
9.
Naylor GM, Gotoda T, Dixon M, et al. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut. 2006;55(11):1545–52 (Epub 2006/04/11).CrossRefPubMedPubMedCentral
10.
Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer. 2004;4(9):688–94 (Epub 2004/09/03).CrossRefPubMed
11.
Higashi H, Tsutsumi R, Fujita A, et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci USA. 2002;99(22):14428–33 (Epub 2002/10/23).CrossRefPubMedPubMedCentral
12.
Azuma T. Helicobacter pylori CagA protein variation associated with gastric cancer in Asia. J Gastroenterol. 2004;39(2):97–103 (Epub 2004/04/08).CrossRefPubMed
13.
Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science. 2002;295(5555):683–6 (Epub 2001/12/18).CrossRefPubMed
14.
Kamada T, Haruma K, Ito M, et al. Time Trends in Helicobacter pylori Infection and Atrophic Gastritis Over 40 Years in Japan. Helicobacter. 2015;20(3):192–8 (Epub 2015/01/13).CrossRefPubMed
15.
16.
17.
Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol. 2007;45(12):4006–10 (Epub 2007/10/19).CrossRefPubMedPubMedCentral
18.
Nishizawa T, Suzuki H, Tsugawa H, et al. Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication. Antimicrob Agents Chemother. 2011;55(6):3012–4 (Epub 2011/04/14).CrossRefPubMedPubMedCentral
19.
Hashinaga M, Okimoto T, Kodama M, et al. Drug resistance in Japan; the present status of Helicobacter pylori; the totaled results of the resistant strain survey in 2013 and 2014, wagakunini okeru yakuzaitaisei Helicobacter pylori no genjo—2013–2014 nendo taiseikin surveillance no syuukei houkoku. Jpn J Helicobacter Res. 2016;17:45–9.
20.
An B, Moon BS, Kim H, et al. Antibiotic resistance in Helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea. Ann. Lab Med. 2013;33(6):415–9 (Epub 2013/11/10).CrossRef
21.
Zhang YX, Zhou LY, Song ZQ, et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J Gastroenterol. 2015;21(9):2786–92 (Epub 2015/03/12).CrossRefPubMedPubMedCentral
22.
Chang WL, Sheu BS, Cheng HC, et al. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol. 2009;24(7):1230–5 (Epub 2009/05/30).CrossRefPubMed
23.
Binh TT, Shiota S, Nguyen LT, et al. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol. 2013;47(3):233–8 (Epub 2012/10/24).CrossRefPubMedPubMedCentral
24.
Gehlot V, Mahant S, Mukhopadhyay AK, et al. Antimicrobial susceptibility profiles of Helicobacter pylori isolated from patients in North India. J Glob Antimicrob Res. 2016;5:51–6 (Epub 2016/07/21).CrossRef
25.
Caliskan R, Tokman HB, Erzin Y, et al. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop. 2015;48(3):278–84 (Epub 2015/06/25).CrossRefPubMed
26.
Saracino IM, Zullo A, Holton J, et al. High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. J Gastrointestin Liver Dis. 2012;21(4):363–5 (Epub 2012/12/21).PubMed
27.
Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, et al. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. Helicobacter. 2012;17(4):269–76 (Epub 2012/07/05).CrossRefPubMed
28.
Suzuki H, Nishizawa T, Hibi T. Helicobacter pylori eradication therapy. Future Microbiol. 2010;5(4):639–48 (Epub 2010/04/01).CrossRefPubMed
29.
Boyanova L, Gergova G, Nikolov R, et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008;60(4):409–15 (Epub 2008/02/06).CrossRefPubMed
30.
Storskrubb T, Aro P, Ronkainen J, et al. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter. 2006;11(4):224–30 (Epub 2006/08/03).CrossRefPubMed
31.
Kupcinskas J, Leja M. Management of Helicobacter pylori-related diseases in the Baltic States. Dig Dis. 2014;32(3):295–301 (Epub 2014/04/16).CrossRefPubMed
32.
Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis. 2004;10(6):1088–94 (Epub 2004/06/23).CrossRefPubMedPubMedCentral
33.
Torres J, Camorlinga-Ponce M, Perez-Perez G, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol. 2001;39(7):2677–80 (Epub 2001/06/28).CrossRefPubMedPubMedCentral
34.
Eisig JN, Silva FM, Barbuti RC, et al. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol. 2011;48(4):261–4 (Epub 2011/12/08).CrossRefPubMed
35.
Nishizawa T, Suzuki H, Hibi T. Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication. J Clin Biochem Nutr. 2009;44(2):119–24 (Epub 2009/03/25).CrossRefPubMedPubMedCentral
36.
Kawai T, Takahashi S, Suzuki H, et al. Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). J Gastroenterol Hepatol. 2014;29(Suppl 4):29–32 (Epub 2014/12/19).CrossRefPubMed
37.
Heep M, Beck D, Bayerdorffer E, et al. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother. 1999;43(6):1497–9 (Epub 1999/05/29).PubMedPubMedCentral
38.
Nishizawa T, Suzuki H, Matsuzaki J, et al. Helicobacter pylori resistance to rifabutin in the last 7 years. Antimicrob Agents Chemother. 2011;55(11):5374–5 (Epub 2011/09/08).CrossRefPubMedPubMedCentral
39.
Suzuki S, Suzuki H, Nishizawa T, et al. Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori. Digestion. 2009;79(1):1–4 (Epub 2009/01/15).CrossRefPubMed
40.
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30 (Epub 2016/11/02).CrossRefPubMed
41.
Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439–46 (Epub 2016/03/05).CrossRefPubMedPubMedCentral
42.
Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 2014;20(30):10338–47 (Epub 2014/08/19).CrossRefPubMedPubMedCentral
43.
Wang L, Lin Z, Chen S, et al. Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China. Clin Microbiol Infect. 2017;23(6):391–5 (Epub 2017/01/13).CrossRefPubMed
44.
Muller N, Amiot A, Le Thuaut A, et al. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clin Res Hepatol Gastroenterol. 2016;40(4):517–24 (Epub 2016/02/07).CrossRefPubMed
45.
Nishizawa T, Maekawa T, Watanabe N, et al. Clarithromycin versus metronidazole as first-line Helicobacter pylori eradication: a multicenter, prospective, randomized controlled study in Japan. J Clin Gastroenterol. 2015;49(6):468–71 (Epub 2014/06/13).PubMed
46.
Asaoka D, Nagahara A, Matsuhisa T, et al. Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area. Helicobacter. 2013;18(6):468–72 (Epub 2013/06/19).CrossRefPubMed
47.
Zullo A, Esposito G, Ridola L, et al. Prevalence of lesions detected at upper endoscopy: an Italian survey. Eur J Intern Med. 2014;25(8):772–6 (Epub 2014/09/24).CrossRefPubMed
48.
Gisbert JP, Gisbert JL, Marcos S, et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006;24(10):1469–74 (Epub 2006/10/13).CrossRefPubMed
49.
Murakami K, Furuta T, Ando T, et al. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol. 2013;48(10):1128–35 (Epub 2013/01/12).CrossRefPubMed
50.
Okimoto K, Arai M, Saito K, et al. Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies. Int Sch Res Not. 2014;2014:631501 (Epub 2014/01/01).PubMedPubMedCentral
51.
Paoluzi OA, Del Vecchio Blanco G, Visconti E, et al. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World J Gastroenterol. 2015;21(21):6698–705 (Epub 2015/06/16).CrossRefPubMedPubMedCentral
52.
Liou JM, Chang CY, Sheng WH, et al. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother. 2011;55(3):1123–9 (Epub 2010/12/30).CrossRefPubMed
53.
Perna F, Zullo A, Ricci C, et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis. 2007;39(11):1001–5 (Epub 2007/09/25).CrossRefPubMed
54.
Matsuzaki J, Suzuki H, Nishizawa T, et al. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. Antimicrob Agents Chemother. 2012;56(3):1643–5 (Epub 2011/12/29).CrossRefPubMedPubMedCentral
55.
Mori H, Suzuki H, Matsuzaki J, et al. Efficacy of 10-day sitafloxacin-containing third-line rescue therapies for Helicobacter pylori strains containing the gyrA mutation. Helicobacter. 2016;21(4):286–94 (Epub 2015/11/28).CrossRefPubMed
56.
Suzuki H, Nishizawa T, Muraoka H, et al. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother. 2009;53(4):1720–1 (Epub 2009/02/04).CrossRefPubMedPubMedCentral
57.
Matsuzaki J, Suzuki H, Tsugawa H, et al. Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy. J Gastroenterol Hepatol. 2010;25(Suppl 1):S7–10 (Epub 2010/07/14).CrossRefPubMed
58.
59.
Mori H, Suzuki H, Matsuzaki J, et al. Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens. United Eur Gastroenterol J. 2017. https://​doi.​org/​10.​1177/​2050640617737215​.
60.
Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther. 2006;24(2):395–403 (Epub 2006/07/18).CrossRefPubMed
61.
Gisbert JP, Castro-Fernandez M, Perez-Aisa A, et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther. 2012;35(8):941–7 (Epub 2012/03/01).CrossRefPubMed
62.
Perri F, Festa V, Clemente R, et al. Randomized study of two “rescue” therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 2001;96(1):58–62 (Epub 2001/02/24).PubMed
63.
Mori H, Suzuki H, Matsuzaki J, et al. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study. United Eur Gastroenterol J. 2016;4(3):380–7 (Epub 2016/07/13).CrossRef
64.
Ciccaglione AF, Tavani R, Grossi L, et al. Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection: two pilot studies. Helicobacter. 2016;21(5):375–81 (Epub 2016/01/26).CrossRefPubMed
65.
Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35(2):209–21 (Epub 2011/12/02).CrossRefPubMed
66.
Lim HC, Lee YJ, An B, et al. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter. 2014;19(6):455–61 (Epub 2014/09/19).CrossRefPubMedPubMedCentral
67.
Nishizawa T, Suzuki H, Maekawa T, et al. Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction. World J Gastroenterol. 2012;18(21):2735–8 (Epub 2012/06/13).CrossRefPubMedPubMedCentral
68.
Nishizawa T, Suzuki H, Fujimoto A, et al. Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection. J Clin Biochem Nutr. 2017;60(3):208–10 (Epub 2017/06/07).CrossRefPubMedPubMedCentral
69.
Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392–7 (Epub 2008/08/05).CrossRefPubMed
70.
Yoon SB, Park JM, Lim CH, et al. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter. 2014;19(4):243–8 (Epub 2014/07/25).CrossRefPubMed
71.
Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174 (Epub 2014/05/23).CrossRefPubMedPubMedCentral
72.
Take S, Mizuno M, Ishiki K, et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol. 2011;46(3):318–24 (Epub 2010/11/26).CrossRefPubMed
Metadata
Title
World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat
Authors
Hidekazu Suzuki
Hideki Mori
Publication date
01-03-2018
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 3/2018
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-017-1407-1

Other articles of this Issue 3/2018

Journal of Gastroenterology 3/2018 Go to the issue

Original Article—Alimentary Tract

The identification of celiac disease in asymptomatic children: the Generation R Study

Original Article—Liver, Pancreas, and Biliary Tract

Basophils activated via TLR signaling may contribute to pathophysiology of type 1 autoimmune pancreatitis

Original Article―Alimentary Tract

A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis

Original Article—Alimentary Tract

Comparison of propofol with midazolam in endoscopic submucosal dissection for esophageal squamous cell carcinoma: a randomized controlled trial

Acknowledgment

Acknowledgements

Review

Current and future pharmacological therapies for NAFLD/NASH
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits